Preprint Article Version 1 NOT YET PEER-REVIEWED

Study the Impact of Glucose-6-phosphatase Activity in Type 2 Diabetic Patients and Non Diabetic Counterparts

  1. Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq
  2. Department of Pharmaceutical Chemistry, College of Pharmacy, Al-Nahrain University, Baghdad, Iraq
  3. Department of Chemistry, College of Science, University of Al-Mustansiriyah, Baghdad, Iraq
  4. Environmental Research Center, University of Technology, Baghdad, Iraq
Version 1 : Received: 30 October 2016 / Approved: 31 October 2016 / Online: 31 October 2016 (08:35:41 CET)

How to cite: Jawad, A.; Ibrahim, A.; Alsayed, R.; Hallab, Z.; Al-Qaisi, Z.; Al-Amery, A.; Yousif, E. Study the Impact of Glucose-6-phosphatase Activity in Type 2 Diabetic Patients and Non Diabetic Counterparts. Preprints 2016, 2016100137 (doi: 10.20944/preprints201610.0137.v1). Jawad, A.; Ibrahim, A.; Alsayed, R.; Hallab, Z.; Al-Qaisi, Z.; Al-Amery, A.; Yousif, E. Study the Impact of Glucose-6-phosphatase Activity in Type 2 Diabetic Patients and Non Diabetic Counterparts. Preprints 2016, 2016100137 (doi: 10.20944/preprints201610.0137.v1).

Abstract

Glucose-6-phosphatase (G6Pase), an enzyme found mostly in the kidneys and the liver, acting significant role of supplying glucose through starvation. This study includes (84) subjects, their age ranged from (40 to 54) years. (20) subjects were healthy chosen as control group and (64) patients with type 2 diabetes mellitus were divided into three groups according to their type of anti diabetic therapy : (23) newly diagnosed group without therapy (Group1), (20) with metformin therapy (Group2) and (21) with metformin plus glibenclamide therapies( Group3). The study found that G-6-Pase activity is increased, thereby leading to an increase in endogenous glucose production (EGP) in patients with type 2 diabetes and, therefore FPG will increase. The result found that increasing G-6-Pase activity will increase the concentration of glucose in the blood and that will increase the long-term glycemic control (HbA1c%).

Subject Areas

glibenclamide therapies; glycemic; Glucose-6-phosphatase

Readers' Comments and Ratings (1)

Importance: How significant is the paper to the field?
Outstanding/highlight paper
100%
Significant contribution
0%
Incremental contribution
0%
No contribution
0%
Soundness of evidence/arguments presented:
Conclusions well supported
100%
Most conclusions supported (minor revision needed)
0%
Incomplete evidence (major revision needed)
0%
Hypothesis, unsupported conclusions, or proof-of-principle
0%
Comment 1
Received: 31 October 2016
Commenter: omr
Commenter's Affiliation: UKM
The commenter has declared there is no conflict of interests.
Comment: Just need the make ref. uniform
+ Respond to this comment
Discuss and rate this article
Views 87
Downloads 80
Comments 1
Metrics 0
Discuss and rate this article

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.